International Journal of Medical Laboratory

81-84

Authors: Mohadeseh Kamali 1 M.D., Akbar Mehralizadeh 2 Ph.D., Mehdi Taheri Sarvtin 3* Ph.D.

Background and Aims: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a global problem and the most common cause of jaundice in neonates. Hence, this study was conducted to investigate the prevalence of G6PD deficiency in Jiroft city in southern Kerman. Materials and Methods: This descriptive cross-sectional study was carried out from 2016 to 2019. Blood samples were taken from all patients referred to Imam Hospital in Jiroft city in southern Iran. The G6PD enzyme activity was evaluated by a fluorescent spot test. Results and Conclusions: In the present study, a total of 7791 newborns were included. Abnormal activity of G6PD was seen in 779 (10%) subjects. Out of 779 patients, 728 (9.4%) were found to be G6PD deficient, and 49 (0.6%) exhibited partial deficiency. A relatively high percentage of G6PD deficiency was seen in newborns of Jirof city. We strongly recommend screening for G6PD enzyme activity in all newborns in this city.

100-109

Authors: A Brief Review of the Association between Genetic Polymorphisms of the Paraoxonase Family and Atherosclerosis

Atherosclerosis is known as an inflammatory disease that can affect any vessel in the body. The occurrence of atherosclerosis in heart vessels is called coronary artery disease (CAD). CAD is one of the most significant causes of morbidity and mortality in developed countries. Different genetic and environmental factors can cause cardiovascular diseases, such as age, weight, sex, and low high-density lipoproteins (HDL) levels. Antioxidant and anti-atherogenic effects of HDL are related to proteins attached, such as Paraoxonase (PON). The Paraoxonase gene family has three members, PON-I, PON-II, and PON-III, located next to each other, on the long arm of chromosome 7, in humans. It seems polymorphisms and genetic variation resulting in several different phenotypes can affect the PON function. Due to its role in the human antioxidant system, changes in paraoxonase activity can increase or even reduce the risk of CAD. In this investigation, we reviewed different studies that showed, in some populations, specific polymorphisms with an effect on enzymatic activity ultimately increase or decrease the risk of disease in individuals. In contrast, no association has been found between disease and polymorphism in some populations. Therefore, further studies and metaanalyses in this field seem to be useful.

122-130

Authors: Ali Volkan Ozdemir 1* M.D., Soycan Mizrak 2 M.D., Arzu Etem Akaağaç 1 M.D.

Background and Aims: As a method for the diagnosis and management of sepsis, the serum procalcitonin assay is routinely used, especially in the emergency department (ED) and intensive care units (ICU). Procalcitonin has reasonable diagnostic accuracy for bacteremia in hospitalized patients of all age groups with suspected infection or sepsis. This study aimed to compare the Getein Biotech procalcitonin point of care method with the ADVIA Centaur® BRAHMS serum procalcitonin method. Materials and Methods: Linearity,recovery, accuracy, and imprecision studies were carried out to evaluate the analytical performance. Bland-Altman plots and Passing-Bablok regression analysis were used to compare patient results. The Kappa test assessed the concordance between the results at cut-off levels of 0.5ng/mL and 2.0ng/mL. Results: In the linearity study performed by obtaining serial dilutions from high and low-level serum pools, the regression equations were "y=-0.03(-0.07 to 0.05)+1.01(0.7 to 1.08)x" and "y=0.463(-1.16 to 2.01)+0.912(0.72 to 1.04)x" respectively. There is no deviation from linearity with the Cusum test (p=0.99 and 0.57). Average recovery value:86%. The CV% values of Control Level-1,2 were 3.75% and 4.2%. 0.1-50.0ng/ml range shows deviation from linearity determined by Cusum test (p=0.01). There was no deviation from linearity in the range of 0.1-2.0ng/ml (p=0.42). Kappa values were calculated as 0.864 and 0.800 (p<0.001). Conclusions: Getein1600 Procalcitonin test should be used for triage or screening purposes. However, a high constant error and deviation from linearity detected at high concentrations indicate that this test should not be used to initiate an antibiotic therapy or alter the current therapy course.

141-149

Authors: Zahra Gholamzadeh Virany 1 M.Sc., Parisa Bagheri 2 M.Sc., Saeedeh Hajebi Khaniki 3 Ph.D., Zahra Chehreghani 2 M.Sc., Hamid Reza Rahimi 4* MD., Ph.D. 1

Background and Aims: Detection of overexpression in tumor-inhibiting genes provides valuable information for leukemia diagnosis and prognosis. Chronic myeloid leukemia (CML) is a stem cell disorder determined by a well-defined genetic anomaly involving BCR-ABL translocation in the Philadelphia chromosome. Curcumin is a chemo-preventive agent for the primary cancer targets, such as the breast, prostate, lung, stomach, duodenum, colon cancers, and leukemias. Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor that treats CML. This study aimed to investigate Curcumin and Imatinib's effect on K562, a human CML cell line that expresses p210 BCR-ABL. Materials and Methods: In this study, Curcumin nanomicelles and Imatinib's apoptotic effects on the K562 cells and the expression of BCRABL were studied. BCR-ABL gene expression was evaluated using realtime polymerase chain reaction. Results: The findings indicated a decrease in the desired gene expression, but the BCR-ABL gene expression of the samples treated with Curcumin nanomicelles did not differ significantly from Imatinib (group control). The amount fold change of the BCR-ABL gene for Imatinib and Curcumin nanomicelle was 0.497 and 0.540, respectively. Conclusions: The present study showed that treating cellular category k562 with Curcumin nanomicelle and Imatinib reduces the BCR-ABL gene expression. Also, data showed that the Curcumin nanomicelle and Imatinib induced the apoptotic process.